Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Neuropharmacology. 2019 Apr 7;158:107598. doi: 10.1016/j.neuropharm.2019.04.004

Figure 3. The efficacy of MCC22 increased over time.

Figure 3.

A sub-therapeutic dose of MCC22 (0.1 fmol) given intrathecally was administered once per week for 16 weeks after cisplatin treatment. Paw withdrawal frequencies were determined before (baseline) and at 20 min after MCC22 injection at weeks 2, 5, 9, and 16 after cisplatin treatment; *p<0.001. A single 0.1 fmol dose of MCC22 in week 16 (day 112) to MCC22 naïve mice shows no hysteresis of action. Data are presented as means (±SEM); n = 8–20 mice. # indicates a difference in paw withdrawal frequency in response to cisplatin as compared to baseline; * indicates a difference in paw withdrawal frequency when treated with MCC22 as compared to values following cisplatin; (**p<0.01, ***p<0.001, ###p<0.001).